Palisades Investment Partners’s CorMedix CRMD Stock Holding History

Palisades Investment Partners’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.35M	Sell	426,543 -183,605	-30%	-$1.45M	0.95%	36
2026 Q1	$4.14M	Buy	610,148 +33,389	+6%	+$247K	1.62%	29
2025 Q4	$6.71M	Buy	576,759 +12,653	+2%	+$140K	2.53%	14
2025 Q3	$6.56M	Buy	564,106 +1,579	+0.3%	+$19.1K	2.58%	13
2025 Q2	$6.93M	Buy	562,527 +203,557	+57%	+$2.25M	3.03%	11
2025 Q1	$2.21M	Sell	358,970 -5,049	-1%	-$52.3K	1.11%	32
2024 Q4	$2.95M	Buy	+364,019	New	+$3.64M	1.24%	30

Other funds holding CRMD

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

WWA

Wingate Wealth Advisors Lexington, Massachusetts $227M AUM 18.87% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

AFA

American Financial Advisors Marietta, Georgia $831M AUM 21.38% 1-Year Est. Return

Palisades Investment Partners's CRMD Position: Q2 2026 in Review

Palisades Investment Partners reduced its CorMedix (CRMD) stake by 30% in Q2 2026, selling an estimated $1.45M and leaving 426,543 shares worth $3.35M. The position accounts for 0.95% of the portfolio, ranked #36.

Palisades Investment Partners first reported a position in CRMD in Q4 2024 and has held it in 7 quarters since. The position peaked at $6.93M in Q2 2025. 40 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Palisades Investment Partners held 426,543 shares of CorMedix worth $3.35M as of Q2 2026.
Palisades Investment Partners sold 183,605 CorMedix shares in Q2 2026, an estimated $1.45M.
CorMedix made up 0.95% of Palisades Investment Partners's portfolio in Q2 2026, its #36 holding.
Palisades Investment Partners first reported a position in CorMedix in Q4 2024 and has held it in 7 quarters since.
Palisades Investment Partners's CorMedix position peaked at $6.93M in Q2 2025.
40 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Palisades Investment Partners's 13F filing for Q2 2026, filed 4 Aug 2026.